original RESUMOObjetivo. Descrever as características, os fatores prognósticos e a sobrevida global de pacientes com síndrome de compressão após metás-tase óssea secundária ao câncer de mama. Método: Foi realizado um estudo de sobrevida em mulheres com câncer de mama e metástase óssea , com diagnóstico de síndrome de compressão medular ou radicular em uma única instituição. As características demográficas (idade, estado civil e escolaridade) e clínicas (estadiamento clínico, tratamento cirúrgico do câncer de mama, sítio da metástase, tipo de compressão e óbito) foram coletadas retrospectivamente dos prontuários médicos. Foi considerado desfecho a ocorrência de óbito e censura, os casos vivos no último seguimento. Foi realizada a Regressão de Cox com nível de significância de 95%. Resultados: Foram incluídos 36 casos. O tempo mediano entre o diagnóstico de câncer de mama e a metástase óssea foi de 17 meses (0-167). O óbito ocorreu em 92% dos casos, com mediana de 22 meses (1-99) após o diagnóstico de metástase óssea e 9 meses (0-47) após o diagnóstico de síndrome de compressão. A única variável associada a com o aumento da sobrevida após compressão medular foi o uso de bifosfonatos após a metástase óssea. Conclusão: A sobrevida global após metástase óssea foi de 22 meses e após a sindrome de compressão de 9 meses. O uso de bifosfonatos aumentou a sobrevida global após a síndrome de compressão medular.Unitermos. Neoplasias da Mama, Síndromes de Compressão Nervosa, Taxa de Sobrevida, Metástase Neoplásica Citação. Bergmann A, Fabro EN, Silva BA, Ribeiro ACP, Lou M, Oliveira JF, Pedrosa E, Thuler LCS. Sobrevida de mulheres com sín-drome de compressão medular após metástase óssea secundária ao câncer de mama. ABSTRACTObjective: describe the characteristics, associated prognostic factors and overall survival of patients with spinal compression syndrome after bone metastasis in breast cancer patients. Method: A survival study was performed in women with breast cancer and bone metastasis, with diagnosis of radicular and/or spinal compression syndrome at a single institution. We retrospectively collect the variables related to demographic characteristics (age, marital status and education) and clinical information (clinical stage, surgical treatment of breast cancer, site of metastasis, type of compression syndrome and death). Outcome was considered the occurrence of death and censures, the cases alive at the last follow-up. Cox regression was used on a statistically significant level of 95%. Results: Thirty-six cases were included. Median time between breast cancer diagnosis and bone metastasis was 17 months (0-167), and median time to compression syndrome was 30 months (0-167). Death occurred in 92% of cases, a median of 22 months (1-99) after bone metastasis diagnosis and 9 months (0-47) after diagnosis of compression syndrome. The only variable that was associated with increased survival after compression syndrome was the use of bisphosphonates after bone metastasis. Conclusion: Overall survival was 22 months after di...

Objective: describe the characteristics, associated prognostic factors and overall survival of patients with spinal compression syndrome after bone metastasis in breast cancer patients. Method: A survival study was performed in women with breast cancer and bone me­tastasis, with diagnosis of radicular and/or spinal compression syn­drome at a single institution. We retrospectively collect the variables related to demographic characteristics (age, marital status and educa­tion) and clinical information (clinical stage, surgical treatment of breast cancer, site of metastasis, type of compression syndrome and death). Outcome was considered the occurrence of death and cen­sures, the cases alive at the last follow-up. Cox regression was used on a statistically significant level of 95%. Results: Thirty-six cases were included. Median time between breast cancer diagnosis and bone metastasis was 17 months (0–167), and median time to compression syndrome was 30 months (0–167). Death occurred in 92% of cases, a median of 22 months (1–99) after bone metastasis diagnosis and 9 months (0–47) after diagnosis of compression syndrome. The only variable that was associated with increased survival after compres­sion syndrome was the use of bisphosphonates after bone metastasis. Conclusion: Overall survival was 22 months after diagnosis of bone metastasis and 9 months after compression syndrome. Patients that had used bisphosphonates had increased survival after compression syndrome.

Background: Cancer may be linked to the risk of deep vein thrombosis, as well as cancer therapies, location and extent. In relation to breast cancer, the risk to develop venous thromboembolism (VTE) is 4 fold more when compared with patients of equivalent age without cancer. Aims: To evaluate the incidence of deep vein thrombosis (DVT) in the cohort of women diagnosed with breast cancer, between 2007 and 2009, at the Brazilian National Cancer Institute (INCA). Methods: A retrospective observational study in a hospital cohort of 4,413 women diagnosed with breast cancer between 2007-2009, and followed by 60 months. The databases were the hospital-based cancer registry of Brazilian National Cancer Institute-Cancer Hospital III and medical records. Outcome was defined as first episode of deep venous thrombosis, determined by Ultrasound Doppler. Cumulative incidence analyzes were performed using the survival functions by Kaplan-Meier method and Hazard ratios determined by Cox Regression. Results: The conditional probability of developing deep vein thrombosis after diagnosis of breast cancer was 2.7% (n=105) at 60 months of followup, and chemotherapy was the most important risk factor for DVT (adjusted HR=4.97; 95% CI 2.68-9.21). Conclusions: The incidence of deep vein thrombosis in this cohort of women diagnosed with breast cancer was low and remained relatively constant during the study time.